20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Earlier today, Viking Therapeutics Inc (NASDAQ:VKTX) announced the first-in-human single-ascending dose and multiple-ascending dose data of VK2735.
- All cohorts showed up to 7.8% reductions in body weight from baseline and 6% reductions relative to placebo.
- Statistically significant differences compared to placebo were maintained or improved 21 days after the last dose of VK2735 was administered.
- William Blair acknowledges that the data were generated from a small sample size (six to seven patients per dose level and ten patients for placebo). The dose-response relationship strengthens the quality of the data.
- The magnitude of the weight loss is similar to Amgen Inc's (NASDAQ:AMGN) AMG133, which demonstrated roughly 6.0%-7.5% placebo-adjusted weight loss after four weeks.
- Viking management stated that no plateauing was observed, which could expand dosing opportunities to maximize the therapeutic effect.
- In parallel, the ability to examine longer titration intervals (typically four weeks) will likely lead to reduced incidence of nausea, vomiting, and gastrointestinal adverse events.
- The analyst writes that the weight loss effect reaches a plateau with Novo Nordisk A/S's (NYSE:NVO) Wegovy and Eli Lilly And Co's (NYSE:LLY) Mounjaro at around the 1- to 1.5-year mark.
- Price Action: VKTX shares are up 64.50% at $15.00 on the last check Tuesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!